# OnCo record penpulimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/penpulimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "penpulimab" ;
  schema:name "Penpulimab"@en ;
  schema:description "Penpulimab is a Chinese PD-1 antibody approved in the US in 2025 for nasopharyngeal carcinoma, the second after toripalimab."@en ;
  schema:url <https://onco.cc/drugs/penpulimab/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Penpulimab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q131626125> ;
  schema:citation <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Anti-PD-1 monoclonal antibody (IgG1, Fc-engineered null)" ;
  schema:alternateName "Penpulimab-kcqx" ;
  onco:approval "CN 2021: Relapsed/refractory classical Hodgkin lymphoma; later NPC, NSCLC", "US 2025: Recurrent or metastatic non-keratinising NPC with cisplatin-gemcitabine; monotherapy after platinum and ≥1 other line" ;
  onco:cancers <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/akeso/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:trials <https://onco.cc/trials/nct05862337/>, <https://onco.cc/trials/nct04974398/>, <https://onco.cc/trials/nct06821503/>, <https://onco.cc/trials/nct06825494/> .